The estimated Net Worth of Life Science Ventures Vii L... is at least $1.53 Million dollars as of 1 August 2018. Life L owns over 275,000 units of Acer Therapeutics Inc stock worth over $1,527,938 and over the last 6 years Life sold ACER stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Life L ACER stock SEC Form 4 insiders trading
Life has made over 1 trades of the Acer Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Life bought 275,000 units of ACER stock worth $4,950,000 on 1 August 2018.
The largest trade Life's ever made was buying 275,000 units of Acer Therapeutics Inc stock on 1 August 2018 worth over $4,950,000. On average, Life trades about 275,000 units every 0 days since 2018. As of 1 August 2018 Life still owns at least 1,697,709 units of Acer Therapeutics Inc stock.
You can see the complete history of Life L stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Life L's mailing address?
Life's mailing address filed with the SEC is Fourth Floor, 470 Atlantic Ave, Boston, MA 02210, USA.
Insiders trading at Acer Therapeutics Inc
Over the last 7 years, insiders at Acer Therapeutics Inc have traded over $0 worth of Acer Therapeutics Inc stock and bought 2,078,411 units worth $11,295,691 . The most active insiders traders include Steve Aselage, Chris Schelling, and Life Science Ventures Vi Gm.... On average, Acer Therapeutics Inc executives and independent directors trade stock every 165 days with the average trade being worth of $170,051. The most recent stock trade was executed by Chris Schelling on 29 November 2022, trading 819,672 units of ACER stock currently worth $1,000,000.
What does Acer Therapeutics Inc do?
acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica
What does Acer Therapeutics Inc's logo look like?
Complete history of Life L stock trades at Acer Therapeutics Inc
Acer Therapeutics Inc executives and stock owners
Acer Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Christopher Schelling,
Founder, Pres, CEO & Director -
Harry S. Palmin,
COO & CFO -
Donald R. Joseph J.D.,
Chief Legal Officer & Sec. -
Dr. Adrian Quartel FFPM, M.D.,
Chief Medical Officer -
John Hilton,
VP of Marketing & Strategic Insights -
Jason Kneeland CPA,
VP of Fin. & Controller -
Matthew T. Seibt,
Chief Commercial Officer -
Jefferson E. Davis,
Chief Bus. Officer -
Bernie Paul,
VP of HR -
John Michael Klopp,
Chief Technical Officer -
John Michael Klopp,
Chief Technical Officer -
Matthew Seibt,
Chief Commercial Officer -
Life Science Ventures Vi Gm...,
-
Robert D Steiner,
Chief Medical Officer -
Jason Amello,
Director -
Michelle Renee Griffin,
Director -
John Michael Dunn,
Director -
Steve Aselage,
Director -
Life Science Ventures Vii L...,
-
Salma Jutt Eghbali,
Chief Commercial Officer -
Adrian W Quartel,
Chief Medical Officer -
Donald Joseph,
See Remarks -
Bernard H Paul,
Chief People Officer -
Tanya Hayden,
Chief Operating Officer -
Chris Schelling,
PRESIDENT AND CEO -
Jefferson E Davis,
CHIEF BUSINESS OFFICER -
Harry S Palmin,
CHIEF FINANCIAL OFFICER